سعر بوستاجليبت ميت Bostaglipt Met‏ 50/850مجم 30 قرص 2026

Bostaglipt Met 50/850 mg (sitagliptin + metformin) 30 film-coated tablets, oral antidiabetic combination marketed in Egypt by Boston Pharmaceuticals.

• Most common adverse reactions (5% or more and more common than placebo) when sitagliptin and metformin were started together: diarrhea, upper respiratory tract infection and headache.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)

• Contraindicated in severe renal impairment (eGFR below 30 mL/min/1.73 m2), acute or chronic metabolic acidosis including diabetic ketoacidosis, and history of serious hypersensitivity (e.g. anaphylaxis, angioedema) to sitagliptin or metformin.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)

• Boxed warning: metformin-associated lactic acidosis (sometimes fatal); risk factors include renal impairment, certain drugs (e.g. carbonic anhydrase inhibitors), age 65 or older, radiological contrast studies, surgery, hypoxic states, excessive alcohol intake and hepatic impairment.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)
• Postmarketing reports of acute pancreatitis; discontinue promptly if suspected. Serious hypersensitivity reactions (anaphylaxis, angioedema, exfoliative skin conditions including Stevens-Johnson syndrome) have been reported with sitagliptin.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)
• Metformin may lower vitamin B12 levels; measure hematologic parameters annually and vitamin B12 every 2 to 3 years. Increased risk of hypoglycemia with insulin or an insulin secretagogue; a lower dose of these may be required.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)

• Carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide, dichlorphenamide)May increase the risk of lactic acidosis; consider more frequent monitoring.U.S. National Library of Medicine DailyMed (FDA SPL)
• Drugs that reduce metformin clearance (OCT2/MATE inhibitors)May increase systemic metformin exposure and the risk of lactic acidosis.U.S. National Library of Medicine DailyMed (FDA SPL)

• Limited data with the combination are insufficient to inform drug-associated risk; published metformin studies have not shown a clear association with major birth defects or miscarriage; poorly controlled diabetes carries maternal and fetal risks.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)
• No information on the combination in human milk; metformin is present in human milk in limited studies without reported infant adverse effects; sitagliptin is present in rat milk. Weigh breastfeeding benefits against maternal need.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)

• Assess renal function (eGFR) before starting and periodically; initiation is not recommended at eGFR 30 to less than 45 mL/min/1.73 m2; may need to be stopped at or before iodinated contrast imaging.General active-ingredient information · U.S. National Library of Medicine DailyMed (FDA SPL)

English text not available for this section.